quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 29, 2026

How Datavault AI (DVLT) Reached Its First Profitable Quarter and Set a 2026 Growth Target

View original at finance.yahoo.com
How Datavault AI (DVLT) Reached Its First Profitable Quarter and Set a 2026 Growth Target Datavault AI Inc. (NASDAQ:DVLT) is one of the penny stocks with the potential to rise 1000 percent…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Net profit of $661 thousand for the quarter, which it described as the first in its history

    60% confidence

  • Operating profit improved to $4.2 million from a $6.3 million loss a year earlier

    60% confidence

  • Fourth-quarter revenue reached $33.8 million, up 3,650% year over year

    60% confidence

  • Full-year 2026 revenue target of $200 million would represent nearly 400% year-over-year growth from fiscal 2025

    60% confidence

  • We acknowledge the potential of DVLT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk

    60% confidence

Data points we hold from this source

Datavault AI Inc. · gross margin78 percent
Datavault AI Inc. · working capital116 USD
Datavault AI Inc. · current assets142.9 USD
Datavault AI Inc. · current liabilities26.9 USD
Datavault AI Inc. · long term debt0 USD
Datavault AI Inc. · net income0.661 USD
Datavault AI Inc. · operating profit4.2 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com